Background & objectives: Thrombocytopeniais, defined as a platelet count of less than 150,000/L complicates 7 to 10% of all pregnancies. Etiology of thrombocytopenia in pregnancy may include a ranging from benign disorders such as gestational thrombocytopenia to life threatening syndromes such as the HELLP (Hemolysis, Elevated liver Enzymes, Low Platelet count). The aim of this study was to evaluate frequency of thrombocytopenia in pregnancy among pregnantsrefered to Tonekabon health centers during 2009 .

  Methods: In a cross-sectional study, 150 normal pregnants bearing third trimester and refered to Tonekabon health centers were selected by random simple sampling. Patients´ demographic information and history were obtaied and CBC (complete blood count) test was done. Those pregnants suffered from thrombocytopenia were refered to a hematologist for compeleting tests if needed. Data analysis was done by SPSS 11.5 and chi-square test and p<0.05 was considered as signifcant difference .

  Results: The Prevalence of thrombocytopenia in pregnancy was 12.66% and the highest percent of thrombocytopenia (68%) was observed among nullipars. The cause of 95% of thrombocytopenia in pregnancy was gestational thrombocytopenia and 5% were due to ITP (Idiopathic Thrombocytopenia Purpura). The pregnants who suffered from gestational thrombocytopenia didn’t have any problems and no need to treatment but those who had been experienced ITP, used venous immunoglobin during labor for treatment .

  Conclusion: Gestational thrombocytopenia is the most common cause of the thrombocytopenia in pregnancy and isn’t dangerous for mother and fetus. So, it is no need to be done any intervention .

  Background & Objectives: Bone metastases induce harmful potential complications on the life of patients. Pamidronate reduces skeletal complications in patients with bone metastases. This study evaluated the effect of Pamidronate on bone pain in cancer patients with bone metastasis.

  Methods: This was quasi experimental study carried out at Imam Sajjad hospital in Ramsar on 41 patients with malignancy by convenience sampling. In this study 90 mg of Pamidronate was injected intravenously each month for 3 months. Data collection was done through demographic and clinical data questionnaire and visual analog scale . Data of before and after intervention were compared. Statistical analysis was performed using paired t tests, chi-square, Friedman and Wilcox on tests with SPSS version 11.5 and p<0.05 was considered significant.

  Results: Statistical analysis showed that the most age group (36%) was 50-59 years and the most patients (65.9%) were female. The most common type of cancer was breast (43.9%) and the most common bone metastasis point in the most of patients (65.9%) was diffuse. The most common sites of pain associated with bone were sternum, ischium and T3-T4 vertebrae. Before treatment, the most patients (80.5%) complained of moderate pain whereas after treatment, the majority of them (41.5%) complained of low pain. The results of this study indicated that there was significant difference (p=0.032) between consumption of NSAIDs before and after treatment, but there was no significant difference between consumption of o pium before and after treatment (p=0.096).

  Conclusion: Pamidronate is effective in prevention of losing bone, reduced pain and analgesic consumption . So i t can be used as primary and routine treatment .